Corient Private Wealth LLC Buys 4,253 Shares of ICU Medical, Inc. $ICUI

Corient Private Wealth LLC raised its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 104.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,312 shares of the medical instruments supplier’s stock after purchasing an additional 4,253 shares during the period. Corient Private Wealth LLC’s holdings in ICU Medical were worth $1,189,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Kera Capital Partners Inc. purchased a new stake in shares of ICU Medical during the 4th quarter worth approximately $217,000. Mercer Global Advisors Inc. ADV increased its holdings in shares of ICU Medical by 89.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,815 shares of the medical instruments supplier’s stock worth $687,000 after buying an additional 2,280 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of ICU Medical during the 4th quarter valued at about $634,000. Mackenzie Financial Corp purchased a new stake in shares of ICU Medical during the 4th quarter valued at about $219,000. Finally, XTX Topco Ltd bought a new position in shares of ICU Medical in the 4th quarter valued at about $511,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Up 1.3%

NASDAQ:ICUI opened at $148.46 on Thursday. The company has a market cap of $3.71 billion, a price-to-earnings ratio of 80.25, a price-to-earnings-growth ratio of 2.05 and a beta of 0.76. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $160.29. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The stock has a fifty day simple moving average of $132.62 and a 200-day simple moving average of $138.43.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts anticipate that ICU Medical, Inc. will post 6.5 EPS for the current year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on ICUI. Zacks Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Weiss Ratings raised ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. KeyCorp dropped their target price on ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a report on Monday, April 27th. Finally, Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ICU Medical presently has an average rating of “Buy” and a consensus price target of $168.40.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.